Despite this, clinical responses to anti-PD-1 or anti-PD-L1 antibodies in breast cancer patients have been modest with lower objective response rates and shorter response durations compared to those seen in neoplasms such as melanoma42–46. The gene discussed is PDCD1; the disease is neoplasm.